James Silver
James Silver serves as Co-Founder and Chief Executive Officer of Diatomic Inc. He is an accomplished life sciences entrepreneur and executive, with a robust background spanning the lifecycle of startup and commercial stage companies. He is known as a dealmaker and for his disciplined execution in pursuit of results that matter. James has held pivotal roles in industry including Chief Legal, Regulatory and Administrative Officer at Cognoa, Chief Operating Officer at Oligon, Vice President of Corporate Development at Systems Oncology, and attorney with Wilson Sonsini. James holds a law degree from the University of London.
Israel Jessop
Israel J. Jessop, co-founder and CTO of Diatomic Inc., brings 25 years of medtech expertise to our mission of revolutionizing organ preservation. With leadership experience at Johnson & Johnson, AbbVie, and Vascular Perfusion Solutions, Israel drives our innovative hydrogen-based therapies to extend organ viability and improve transplant outcomes. A prolific inventor with over 20 patents, he has been honored as Innovator of the Year (2015, 2016) at LifeCell for his groundbreaking work in medical devices and tissue engineering. Holding a B.S. in Metallurgical Engineering from Montana Tech and an M.S. in Materials Science from The University of Florida, Israel leads our team with a passion for solving complex challenges and advancing patient care worldwide.
Nick Shea
Dr. Nicholas J. Shea, Chief Medical Officer of Diatomic Inc., is a distinguished cardiac surgeon and innovator, serving as Chief of Cardiac Surgery and Co-Director of the Heart and Vascular Institute at Stamford Health, and Assistant Professor of Surgery at Columbia University Irving Medical Center. With expertise in mitral valve repair, complex aortic arch and root disease, multi-arterial coronary bypass, heart failure, and orthotopic heart and lung transplantation, Dr. Shea brings unparalleled clinical insight to our mission of advancing organ preservation. Holding an MD and M.S. in Biomedical Engineering from Columbia University, he has published extensively on aortic disease, heart failure, and surgical innovation, while contributing to numerous device patents. Board-certified by the American Board of Thoracic Surgery and a fellow of the American College of Cardiology, Dr. Shea drives Diatomic’s development of hydrogen-based therapies to revolutionize heart transplant outcomes.
Alex Ringo
Alex Ringo, co-founder and strategy at Diatomic Inc., brings expertise in market segmentation and differentiation, M&A, and pipeline strategy. Previously, he held commercial, strategic and technical roles at BioTissue, Abbott and LifeCell (an Allergan Company), where he drove corporate development, device design, international product launches, and product management. Alex holds an MBA from Duke University’s Fuqua School of Business and an advanced degree in Biomedical Engineering from the University of Rochester. He is an author on multiple regenerative medicine patents, contributing to advancements in the field.
